Docstoc

Gilead Sciences, Inc. Uses the PHT Corporation LogPad® System for 1st Antianginal Drug to Treat Type 2 Diabetes

Document Sample
Gilead Sciences, Inc. Uses the PHT Corporation LogPad® System for 1st Antianginal Drug to Treat Type 2 Diabetes Powered By Docstoc
					
				
DOCUMENT INFO
Shared By:
Tags:
Stats:
views:0
posted:12/2/2013
language:Unknown
pages:3
Description: BOSTON & GENEVA--(BUSINESS WIRE)--PHT Corp.'s LogPad System was used by Gilead Sciences (NASDAQ: GILD) on Phase 4 TERISA trial to measure antianginal effect of Ranolazine in T2DM patients therapeutic areas of cardiology, endocrinology
EON: Enhanced Online News EON: Enhanced Online News http://eon.businesswire.com
About At EON: Enhanced Online News, we show you how to make your online press release thrive. If you want to drive traffic to your website, generate sales leads, make an announcement, or promote a new product, EON: Enhanced Online News delivers the online visibility that you need. EON: Enhanced Online News powered by Business Wire.